<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20201217049741N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-01-10</date_registration>
      <primary_sponsor>Shahid Rajaei Heart Hospital, Tehran</primary_sponsor>
      <public_title>Assessing The Effects Of  Mild And Moderate Hypothermia On The Cerebral Oxymetery In Acyanotic Congenital Heart Disease Under The Cardiopulmonary Bypass</public_title>
      <acronym></acronym>
      <scientific_title>Assessing The Effects Of  Mild And Moderate Hypothermia On The Cerebral Oxymetery In Acyanotic Congenital Heart Disease Under The Cardiopulmonary Bypass</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-01-09</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>64</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/53195</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: Assignment of individuals to study groups was done in a randomized block method using 4 blocks. This work was done with the relevant software by the professor of statistics. In each block, there were 2 people belonging to group A and two people belonging to group B, whose order was random and the blocks were selected using a table of random numbers, Blinding description: Patients' parents are given explanations about the study and the two groups to be studied, and then they are given consent to enter the study, but they are not told which group they are in.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Congenital Acyanotic heart disease.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients in the mild hypothermia group (32 ° C) are treated as follows. The nasopharyngeal temperature will be maintained above 35 degrees for the time before the onset of cardiopulmonary bypass. For each child, 5 measurements are performed at different intervals: 1- at the time after induction of anesthesia (baseline value), 2- at the time of cooling up to 34 degrees Celsius, 3- at the time of the lowest level of cooling (first group 32 Degrees Celsius), 4- at reheating time (above 34 degrees Celsius), 5- after CPB completion. Intervention 2: Intervention group: Patients in moderate hypothermia (28 ° C) are treated as follows. The nasopharyngeal temperature will be maintained above 35 degrees for the time before the onset of cardiopulmonary bypass. For each child, 5 measurements are performed at different intervals: 1- at the time after induction of anesthesia (baseline value), 2- at the time of cooling up to 34 degrees Celsius, 3- at the time of the lowest level of cooling (28 degrees Celsius), 4- at reheating time (above 34 degrees Celsius), 5- after CPB completion.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is In case of a final decision, I will specify whether or not to publish.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mehran Jafarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr St., Niayesh Intersection, Shahid Rajaei Heart Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 23921</telephone>
        <email>mehran.jafarian1369@gmail.com</email>
        <affiliation>Shahid Rajaei Cardiovascular Hospital, Tehran</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mehran Jafarian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr St., Niayesh Intersection, Shahid Rajaei Heart Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1995614331</zip>
        <telephone>+98 21 23921</telephone>
        <email>Mehran.jafarian1369@gmail.com</email>
        <affiliation>Shahid Rajaei Cardiovascular Hospital, Tehran</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children 1 day to 14 years old undergoing surgery for Acyanotic congenital heart disease with pulmonary heart bypass
Children weighing 5 to 20 kg
No history of neurological diseases
No hepatic or renal insufficiency (creatinine above 2 mg / dL)
No preoperative anemia
No history of preoperative cardiopulmonary resuscitation
Parents' consent to participate in the research project</inclusion_criteria>
      <agemin>1 day</agemin>
      <agemax>14 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Hemodynamic instability
Emergency heart surgery
Lower the temperature during operation to below the desired temperature</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Other</i_code>
      <i_code>Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients in the mild hypothermia group (32 ° C) are treated as follows. The nasopharyngeal temperature will be maintained above 35 degrees for the time before the onset of cardiopulmonary bypass. For each child, 5 measurements are performed at different intervals: 1- at the time after induction of anesthesia (baseline value), 2- at the time of cooling up to 34 degrees Celsius, 3- at the time of the lowest level of cooling (first group 32 Degrees Celsius), 4- at reheating time (above 34 degrees Celsius), 5- after CPB completion.</i_keyword>
      <i_keyword>Intervention group: Patients in moderate hypothermia (28 ° C) are treated as follows. The nasopharyngeal temperature will be maintained above 35 degrees for the time before the onset of cardiopulmonary bypass. For each child, 5 measurements are performed at different intervals: 1- at the time after induction of anesthesia (baseline value), 2- at the time of cooling up to 34 degrees Celsius, 3- at the time of the lowest level of cooling (28 degrees Celsius), 4- at reheating time (above 34 degrees Celsius), 5- after CPB completion.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cerebral oxygenation. Timepoint: 1- At the time after induction of anesthesia (baseline value), 2- At the time of cooling up to 34 degrees Celsius, 3- At the lowest level of cooling (first group 32 degrees Celsius), (second group 28 degrees Celsius), 4 - At the time of reheating (above 34 degrees Celsius), 5-after CPB. Method of measurement: Based on the amount of INVOS.</prim_outcome>
      <prim_outcome>Blood lactate. Timepoint: 1- At the time after induction of anesthesia (baseline value), 2- At the time of cooling up to 34 degrees Celsius, 3- At the lowest level of cooling (first group 32 degrees Celsius), (second group 28 degrees Celsius), 4 - At the time of reheating (above 34 degrees Celsius), 5-after CPB. Method of measurement: Laboratory kits.</prim_outcome>
      <prim_outcome>Incidence of neurological complications. Timepoint: From postoperative time to discharge. Method of measurement: Based on patient records.</prim_outcome>
      <prim_outcome>Average intubation time. Timepoint: From the time of surgery to Extubation. Method of measurement: Based on patient records.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Rajaei Heart Hospital, Tehran</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-25</approval_date>
        <contact_name>Ethics Committee of Shahid Rajaei Heart Hospital, Tehran</contact_name>
        <contact_address>Valiasr St., the intersection of Niayesh Shahid Rajaei Heart Hospital Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
